Theodor Kolobow, M.D., passed away on March 24, 2018. He was 87 years old. His contributions while at the NHLBI to the field of cardiovascular and pulmonary research fall nothing short of extraordinary, and include advancements in the development of artificial organs, and the pathophysiology of acute lung injury. Over the course of his career he was actively involved in the innovation and development of new dialysis machines, cuffless endotracheal tubes, and devices to prop open right-sided heart valves, thereby preventing left heart distention during percutaneous cardiopulmonary bypass. He designed special low-resistance endotracheal tubes to limit the necessary ventilatory pressure, in addition to endotracheal tubes that would help to limit bacterial colonization and methods for preventing ventilator associated pneumonias.
Is the Yanny vs. Laurel debate tearing your office or lab apart? Well, according to NIH IRP investigators, there's no true answer to what this word is. As brain expert Mark Hallett, M.D., of the NIH National Institute of Neurological Disorders and Stroke puts it, "Perception is not reality, however real it seems."
NIH history is rife with legends, scientists who have made remarkable discoveries and incalculable contributions to the health and longevity of humankind. There are living legends; just peruse the “Honors” page on the IRP website to see what I mean. And there are greats who are gone but certainly not forgotten.
It might seem easy to blame your parents for the way you turned out; after all, they raised you and gave you all of your DNA. But, before throwing blame around, consider saving some for the place where you grew up. According to new IRP research, being raised in an urban environment can dramatically alter how your genes influence your brain.1
James F. Holland, M.D., a renowned cancer expert who was a major figure in the development of cancer chemotherapy, died on March 22, 2018, at the age of 92. Dr. Holland was among the first group of research physicians recruited to the NIH Clinical Center, serving as a senior surgeon at the National Cancer Institute from 1953 to 1954. In that short year at the NIH, he initiated a clinical trial to compare continuous or intermittent treatment with two chemotherapy agents for acute leukemia in children: methotrexate and 6-mercaptopurine. Dr. Holland moved to Roswell Park Memorial Institute in Buffalo before the trial was completed, but he continued to collaborate. His work ultimately turned an incurable illness into one with an 80% survival rate. In 1972, he and his NIH collaborators shared the Albert Lasker Clinical Medical Research Award for "outstanding contribution to the concept and application of combination therapy in the treatment of acute leukemia in children."
Most people experience anxiety at some point in their lives, whether it’s pre-speech jitters or sweaty palms when their plane takes off. While mild feelings of nervousness are completely normal and can even be beneficial, anxiety can also have negative repercussions if it causes somebody to completely avoid situations like social encounters or taking a flight to visit distant family.
On Wednesday, May 2, hundreds of researchers gathered at NIH’s Natcher Conference Center to show off their recent discoveries. But unlike a typical scientific conference, the letters “M.D.” and “Ph.D.” were noticeably absent from these scientists’ credentials. Instead, the event — NIH’s annual Postbac Poster Day — celebrated the accomplishments of individuals participating in the NIH Postbaccalaureate Intramural Research Training Award (IRTA) Program.
Ever since the Human Genome Project (HGP) launched in 1990, patients and members of the public have been inundated with predictions about how unraveling the mysteries of genetics will revolutionize healthcare. Today, many of these promises remain unrealized, prompting some to become skeptical of the true utility of this research for improving human health. But, while more work is needed to fully realize the potential of genome-focused medicine, it remains true that patients are benefiting from our knowledge of the human genome in numerous, sometimes under-appreciated ways.
In the midst of the 1957 Asian flu pandemic, doctors and researchers were understandably focused on treating patients and developing ways to contain the outbreak. It wasn’t until 30 years later that scientists began reporting that women who were pregnant when they caught the virus were more likely to have children who would later be diagnosed with schizophrenia.1 While that relationship remains controversial,2 numerous studies have since linked activation of a pregnant woman’s immune system with an increased risk that her child will develop certain psychiatric disorders, including not just schizophrenia but also autism spectrum disorder and major depressive disorder.3 A new IRP study has now expanded on this work by showing that exposure to higher levels of two immune system molecules in utero can noticeably alter the neurological and cognitive development of young children.4
Every forty seconds, someone in the United States suffers a stroke, and researchers across the country are hunting for a way to help brain cells survive these traumatic events. A group of IRP researchers recently discovered a promising new tool to aid in this effort. By blocking the action of a brain chemical called monoacylglycerol lipase (MAGL), the scientists markedly reduced stroke-related brain damage and disability in rats.1
This page was last updated on Friday, January 14, 2022